Marshall on Oncology

 
 

  • Mud Pies: Superfood for the Microbiome?   Too much cleanliness and sanitizing might reduce the effectiveness of our immune system, which could be a contributing cause of illness.
  • 12 Chemo Cycles: More Toxicity Than Therapy?   Dr John Marshall suggests that 12 cycles of chemotherapy in metastatic colorectal cancer exceeds what is needed for maximum tumor regression and often results in toxicity that is better avoided.
  • 'Can Do' Collaborations Speed Progress in GI Cancers   Dr John Marshall reports on two initiatives that harness the collective efforts of advocacy groups, academic researchers, and industry to advance research in GI cancers.
  • HER2+ Colorectal Cancer: Slicing the Pie Into Curable Portions   Dr John Marshall views a study of dual targeting in HER2+ CRC as an argument for combining broad molecular testing and precision medicine to slice the cancer pie into curable portions.
  • CRC Builds Up STEAM in Midst of Blizzard   After digging out from a blizzard, Dr John Marshall discusses highlights from GICS 2016, including molecular testing, new drugs, and key studies results, plus the STEAM trial in colorectal cancer.
  • Can Physicians Help Heal the Body Politic?   Troubled by news reports of growing violence worldwide, Dr John Marshall asks: What can healthcare providers do to cool feverish minds and heal the body politic?
  • Is Chemo Needed in Patients With MSI Colon Cancer?   FOLFOX is standard treatment for stage III colorectal cancer. But for tumors with high microsatellite instability, adjuvant chemotherapy might not be necessary, says Dr John Marshall.
  • ASCO 2015 Raises the Question of Value   Dr John Marshall puts his vacation on hold to highlight the themes of ASCO 2015, including the critical question: What is value in cancer care, and how much is riding on the correct answer?
  • Waves of Emotion, Understanding After PBS Cancer   Dr John Marshall asks clinicians to be mindful of the emotional response cancer patients will have to the PBS Cancer documentary--and to use heightened public awareness to push for research funding.
  • Is 'Conflict of Interest' Hampering Cancer Research?   Dr John Marshall discusses how the current requirements for declaring conflict of interest are complicating cancer research and possibly barring the best minds from working together.
  • Coverage Cut-off for Cancer Costs?   Will US and European guidelines follow the UK's lead and incorporate value metrics in their recommendations? Dr. John Marshall, reporting on a discussion at GICS, says it's only a matter of time.
  • Immuno Death Ray to GI Cancers   Can immunotherapy 'clip the force field' of gastrointestinal tumors? Dr John Marshall and experts say yes and will discuss advances during the Ruesch Symposium 2014, December 5, Washington, DC.
  • Longer Life, at Any Cost?   Dr John Marshall asks his cancer patients on their first visit: How long do you want to live? Their answers have implications for the practice of oncology -- and the healthcare system as a whole.
  • Cologuard: Breakthrough in CRC Screening   Dr. John Marshall discusses Cologuard, a new screening test for colorectal cancer that can detect CRC missed by colonoscopy, which he hopes will keep masses of patients out of his office.
  • Why Don't CRC Survival Data Add Up?   Dr. John Marshall questions why the survival rate in a large phase 3 trial presented at ASCO was nearly double the survival rates achieved by earlier trials while using the same medicines.
  • Dad's Gifts: From Go-Karts to Joy Rides   Dr. John Marshall's father taught him how to fix things, and in the process, set for him an example of joy that fixed him for life.
  • GI Cancer's 'Paparazzi Moment'   Dr. John Marshall says GI cancer's paparazzi moment at ASCO will be the plenary session spotlighting a head-to-head comparison of one biologic class against another in first-line colon disease.
  • Silence the Mouse Model That Roared   Dr. John Marshall says that generous funding of basic science is an inefficient and misdirected use of cancer research dollars. The focus needs to be on innovative, clinical translational research.
  • Resected Pancreatic Cancer: Why Wait for the Inevitable?   Dr. John Marshall reports on a retrospective study suggesting that maintenance with capecitabine is a promising option in patients with resected pancreatic adenocarcinoma after adjuvant therapy.
  • Is Adjuvant Chemo Needed in Rectal Cancer?   Dr. John Marshall asks, 'Why are we giving patients oxaliplatin when our evidence doesn't demonstrate much, if any, benefit?
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.